The National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance (FDG) recommending AQUIPTA® (atogepant), the oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) as an option in suitable patients for preventing migraine i.
Social media platforms, including Facebook, Instagram, and TikTok have been running hundreds of ads for apps that promise AI-generated sexual images and companionship.